The 20 Best Diffuse Midline Glioma H3 K27M-Mutant Doctors Near Me in Ann Arbor, MI

Dr. Koschmann is a Pediatric Neuro-Oncologist in the Department of Pediatrics and a Principal Investigator of an independent translational Pediatric Neuro-Oncology laboratory. His work in the clinic and lab complement and drive each other, resulting in a clear goal to improve therapies for children with brain tumors. He has engaged in research and the clinical care of pediatric brain tumor patients at both Seattle Children’s Hospital and the University of Michigan’s Mott Children’s Hospital. The Koschmann laboratory is exploring the molecular mechanisms by which recurrent mutations in pediatric high-grade glioma (HGG), including glioblastoma (GBM), anaplastic astrocytoma (AA) and diffuse intrinsic pontine glioma (DIPG) promotes tumor formation and affect treatment response.Dr. Koschmann has applied this precision medicine approach in translational and clinical work in Pediatric Neuro-Oncology. Along with researchers and colleagues from multiple clinical divisions at the University of Michigan and other institutions, he developed and co-facilitate the UM CNS Precision Medicine conference. In this multi-disciplinary and multi-institutional conference, molecular results are incorporated from pediatric brain tumor patients (paired tumor/germline sequencing results and pre-clinical cell culture treatment studies) into their treatment. Dr. Koschmann has established new algorithms and are in the process of developing multiple clinical trials incorporating the use of molecularly targeted therapy for pediatric patients with brain tumors. He will serve as PI for these trials and their biologic correlative research. Dr. Koschmann is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Glioma, Brain Stem Cancer, and Embryonal Tumor with Multilayered Rosettes. Dr. Koschmann is board certified in Pediatric Hematology-Oncology and Pediatrics.

Dr. Patricia Robertson, M.D., earned a medical degree at Wayne State University Medical School in Detroit and completed a residency in pediatrics at Children's Hospital of Michigan. She then went on to a fellowship in pediatric neurology at the University of Michigan and trained in pediatric neuro-oncology at New York University Medical Center. Dr. Robertson joined the University of Michigan faculty in 1988. She has a special interest in clinical pediatric neuro-oncology focusing on the evaluation of response, outcome and late effects on the developing nervous system; current treatment strategies for children with central nervous malignancies; and in the development of innovative treatment approaches for this population. Dr. Robertson is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 42 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diencephalic Syndrome, Brain Stem Cancer, and Brain Tumor.

Dr. Andrea (Flynn) Franson received her bachelor's degree from Rensselaer Polytechnic Institute in Troy, New York and her medical degree from the University of Michigan Medical School. She completed her residency in pediatrics and fellowship in pediatric hematology/oncology at the Children's Hospital of Philadelphia (CHOP). During fellowship, she earned a master's degree in Pharmacology from Thomas Jefferson University in Philadelphia. While at CHOP, she was an Alex's Lemonade Stand Foundation Center of Excellence Scholar, through which she had mentored training in clinical trial design and pharmacology. Dr. Franson has focused her research efforts in translational research science, working to transition the most promising compounds into the clinic for children with cancer. Dr. Franson is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, Neuroblastoma, and Bone Marrow Aspiration.

Hugh Garton is a Neurosurgery provider practicing medicine in Ann Arbor, Michigan. Dr. Garton is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 72 other conditions, according to our data. His clinical expertise encompasses Chiari Malformation, Chiari Malformation Type 1, Chiari Malformation Type 2, Posterior Fossa Decompression, and Gamma Knife Radiosurgery. Dr. Garton is board certified in Neurological Surgery.

My past and ongoing research is focused on translational studies and clinical trials for children with brain and spinal cord tumors with a special emphasis on ependymoma and ATRT. Children with brain tumors continue to have poor outcomes compared to those with other cancers in this age group. I have analyzed the outcomes of treatment for ATRT and ependymoma in children, combining traditional modes of therapy, such as surgery, chemotherapy, and radiation therapy, with molecularly targeted therapy. In the process we have identified novel clinical and molecular risk factors associated with outcomes. By identifying clinical risk factors associated with poor outcomes in these children, we can tailor therapy to improve outcomes in those at highest risk of treatment failures. Dr. Upadhyaya is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Teratoma of the Mediastinum, Glioma, Medulloblastoma, and Bone Marrow Aspiration.

Neena Marupudi is a Neurosurgery provider practicing medicine in Ann Arbor, Michigan. Dr. Marupudi is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 53 other conditions, according to our data. Her clinical expertise encompasses Hydrocephalus, Tethered Cord Syndrome, Chiari Malformation Type 1, Rhizotomy, and Laminectomy. Dr. Marupudi is board certified in Neurological Surgery.

Dr. Magge is a Clinical Professor of Neurosurgery and serves as the Surgical Director of the Pediatric Brain Tumor Program. His clinical practice encompasses all types of pediatric neurosurgery, with particular clinical and research interests in pediatric brain tumors, craniosynostosis (endoscopic and open surgery), and pediatric neurovascular disease (including AVM’s and moyamoya disease). His brain tumor research has focused on finding better treatments for diffuse intrinsic pontine gliomas (DIPG’s) and methods for liquid biopsy. He has been involved in multicenter clinical trials. In the field of craniosynostosis, he has been the principal investigator of a multicenter trial examining long term outcomes of children with craniosynostosis treated with either endoscopic or open surgery. He also started the first endoscopic craniosynostosis surgery program in the Washington, DC area and helped to grow a busy craniosynostosis practice in California. He has authored numerous scholarly papers, and he is a regular speaker at national and international conferences. Dr. Magge works to find the best treatment for each patient in the least invasive method possible.Prior to joining University of Michigan Health, Dr. Magge served as the Director of Neurosurgery and Co-Director of the Children’s Hospital of Orange County Neuroscience Institute and Professor of Clinical Neurosurgery at University of California Irvine. Prior to that, he was a faculty member in the Division of Pediatric Neurosurgery at Children’s National Hospital in Washington, DC, where he started the pediatric neurosurgery fellowship program and served as fellowship director.Dr. Magge grew up in Cincinnati, Ohio, and he attended Harvard College for his undergraduate studies, where he majored in biochemistry. He then obtained his medical degree from Harvard Medical School, graduating in 2001. During medical school, he completed a 1 year Howard Hughes research fellowship at the NIH. He then completed neurosurgery residency training at the University of Pennsylvania in 2008, and fellowship training in pediatric neurosurgery at Boston Children’s Hospital in 2009. Dr. Magge is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Craniosynostosis, Plagiocephaly, Cortical Dysplasia, Craniectomy, and Posterior Fossa Decompression. Dr. Magge is board certified in Neurological Surgery and Pediatric Neurosurgery.

Dr. Leung is the Director of the Neuro-Oncology Fellowship Program and is a clinical assistant professor in the Department of Neurology. She sees patients in the Neuro-Oncology Clinic at the Rogel Cancer Center and at the Northville Health Center. She completed a bachelor’s degree at the University of Western Ontario, a master’s degree at the University of Toronto, and medical degree at SUNY Upstate. Dr. Leung completed her Neurology residency and Neuro-Oncology fellowship at Henry Ford Hospital. Dr. Leung is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Metastatic Brain Tumor. Dr. Leung is board certified in Neurology.

Michelle Kim, M.D. is an associate professor in the Department of Radiation Oncology at the University of Michigan. She completed her medical training at Case Western Reserve University and her residency at MD Anderson Cancer Center. Dr. Kim is board-certified in Radiation Oncology by the American Board of Radiology. Her research focus is in the adaptive individualization of radiation therapy using advanced molecular and functional imaging for patients with central nervous system tumors including gliomas and brain metastases. Dr. Kim is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 30 other conditions, according to our data. Her clinical expertise encompasses Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Metastatic Brain Tumor, and Astrocytoma. Dr. Kim is board certified in Radiation Oncology.

Dr. Wahl is a physician scientist at the University of Michigan specializing in cancers of the central nervous system. His research focuses on the development of new treatment strategies for brain tumors and his laboratory group is especially interested in interactions between radiation and abnormal metabolism in glioblastoma. In the clinic, he cares for a wide variety of patients with both malignant and benign tumors of the central nervous system. Dr. Wahl is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Nathan Clarke is a Neurologist practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 10 years. Dr. Clarke is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Brain Tumor, and Glioblastoma. Dr. Clarke is board certified in Neurology.

Karin Muraszko, M.D., grew up in New Jersey and received her undergraduate degree from Yale University. She then continued to Columbia University in New York where she received her medical degree and completed her residency training in Neurological Surgery and completed fellowships in pediatric neurosurgery.Following her training at Columbia, Dr. Muraszko was a researcher at the National Institutes for Health for two years before joining the team at the University of Michigan. From 2005 to 2022, Dr. Muraszko served as the head the Department of Neurosurgery at the University of Michigan. She was the first woman to chair an academic neurosurgery department in the United States.Dr. Muraszko specializes in pediatric neurosurgery. She is board certified by the American Board of Neurological Surgeons, and is a member of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS) along with several pediatric professional associations. Her research interests include Immunotoxin therapy for brain tumors, the biology of brain tumors, Chiari malformations, craniofacial anomalies, congenital anomalies of the brain and spine and hydrocephalus.Dr. Muraszko lives in Ann Arbor with her husband and two children. Dr. Muraszko is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Chiari Malformation, Chiari Malformation Type 2, Tethered Cord Syndrome, Posterior Fossa Decompression, and Bone Graft. Dr. Muraszko is board certified in Neurological Surgery and Pediatric Neurosurgery.

Giulia Benedetti is a Neurologist and a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Benedetti is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Seizures, Generalized Tonic-Clonic Seizure, Absence Seizure, and Lissencephaly 1. Dr. Benedetti is board certified in Neurology W/Spec Qual Child Neuro and Epilepsy.

Dr. Sedig was born and raised in Orlando, Florida. She completed her undergraduate degree in Medical Ethics at Davidson College before returning to Florida to attend the University of Florida College of Medicine. She then went to the University of Wisconsin-Madison for her residency in Pediatrics and then to the University of Michigan for her Pediatric Hematology/Oncology Fellowship. Dr. Sedig is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Retinoblastoma, Hepatoblastoma, Hereditary Neuroblastoma, Neuroblastoma, and Bone Marrow Aspiration.

Rama Rao is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Rao is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 36 other conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Chondrosarcoma, Hereditary Neuroblastoma, Neuroblastoma, and Bone Marrow Aspiration. Dr. Rao is board certified in Pediatric Hematology-Oncology.

Angad Kochar is a Pediatrics specialist and a Pediatric Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Kochar is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Trisomy 13, Seizures, Generalized Tonic-Clonic Seizure, and Camptocormism. Dr. Kochar is board certified in Neurology W/Spec Qual Child Neuro.

Donna Edwards is a Radiation Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Edwards is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her clinical expertise encompasses Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Atypical Teratoid Rhabdoid Tumor (ATRT).

Dr. Wajd Al-Holou was raised in southeast Michigan. After attending the University of Michigan Medical School, where he graduated with the highest award for research, he then began a 7-year Neurosurgery residency at the University of Michigan. Upon completion of residency in 2016, he completed a Complex Neurosurgical Oncology Fellowship at the MD Anderson Cancer Center in Houston, TX. His training focused on the management of complex brain tumors, spinal tumors, and skull base malignancies.Dr. Al-Holou specializes in the management of complex brain tumors, primarily focusing on gliomas and metastases to the brain. Dr. Al-Holou has expertise in the use of awake mapping techniques, microsurgery, and image-guidance to maximize tumor removal in the safest possible manner. He also specializes in the management of meningiomas and spinal tumors.Dr. Al-Holou is the co-founder and co-director of the Michigan Medicine Multidisciplinary Brain Tumor Clinic (M3BTC). As a member of this Neuro-Oncology multidisciplinary team, he works strategically to ensure personalized treatment recommendations that will maximize the benefits for each individual patient.Currently, he is a member of the AANS/CNS Executive Committee of the Section on Tumors. He served as the Co-Chair for Tumor Section Scientific Program for the American Association of Neurological Surgeons (AANS) in 2018 and is a member of the Society of Neuro-Oncology. He also serves as an editor for cancer journal, BMC Cancer.Dr. Al-Holou is committed to research and education in Neurosurgery and his life-long goal is improving the survival and outcomes for patients with tumors. His research interest focuses primarily on understanding the genetic mechanisms of recurrence in glioblastoma, and in identifying precision medicine therapies to target resistant tumors. Dr. Al is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Astrocytoma, Oligodendroglioma, and Awake Craniotomy. Dr. Al is board certified in Neurological Surgery.

Borislav Hristov is a Radiation Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Hristov is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His clinical expertise encompasses Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Diffuse Midline Glioma H3 K27M-Mutant. Dr. Hristov is board certified in Radiation Oncology.

Dr. Jason Heth attended The University of Iowa where he received his medical degree and also completed his residency in Neurosurgery. Dr. Heth then completed additional training in Skull Base Neurosurgery, completing a fellowship at the University of Arkansas for Medical Sciences. After completing his fellowship, he joined the faculty of the University of Michigan. Dr. Heth specializes in brain tumor treatment, including surgical removal, radiosurgery, and basic research. His primary areas of interest focus on gliomas, glioblastoma, brain metastasis, and meningiomas. He is also involved in medical student education and quality improvement programs at the University of Michigan. Dr. Heth is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy. Dr. Heth is board certified in Neurological Surgery.